Connect Sign In
In keeping with its commitment to environmental stewardship, ARUP Laboratories is working with Wasatch Resource Recovery (
Point-of-care antigen testing with the Abbott BinaxNOW COVID-19 Ag Card is not as sensitive as standard NAATs for detecting SARS-CoV-2 in asymptomatic college students, according to a study.
ARUP Laboratories’ medical directors were involved in the publication of more than 115 peer-reviewed articles in academic journals in 2020.
ARUP Laboratories announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious “United Kingdom (UK) variant” of the virus.
The career growth spotlight series shows the myriad career paths possible at ARUP, inside and outside more than 65 laboratories and in more than 180 departments.
ARUP and University of Utah Health continue to research the safety and efficacy of COVID-19 convalescent plasma (CCP) in four multicenter randomized clinical trials.
Utah added screening for GAMT deficiency to its NBS panel in 2015, becoming the first state to do so. It is now one of only three states to screen for the condition.
Which types of innovation, adaptation, and acceleration happened in diagnostic technology companies in the face of the COVID-19 pandemic? Are the intensity and fast-moving strategies even sustainable?
To assist clinicians in providing the best possible care for patients with thyroid disease, ARUP Laboratories has released a comprehensive new thyroid disease testing resource on ARUP Consult.
Adam Barker, PhD, director of the ARUP Institute for Clinical & Experimental Pathology, is among medical experts who will participate in an event that will examine Utah’s response to COVID-19.
A recording of an hour-long webinar updating the status of diagnostic testing for SARS-CoV-2 nearly a year after the first tests were introduced is now available to watch for free.
ARUP Researchers Played Key Role in Newborn Screening That Identified Baby Born with GAMT Deficiency
In December 2020, Utah’s Newborn Screening Program identified the first patient with guanidinoacetate methyltransferase (GAMT) deficiency solely through newborn screening.
